BioNexus Gene Lab Partners with ML Tech to Optimize Ethereum Growth

BioNexus Gene Lab Corp. (BGLC), a leading technology company in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize its Ethereum growth strategies. ML Tech is an artificial intelligence (AI)-powered digital asset management platform regulated by the National Futures Association (NFA) and headquartered in Miami, Florida. The partnership is part of BGLC’s new Ethereum treasury strategy, which underscores its commitment to both technological and financial innovation.

Through this partnership, BGLC will leverage ML Tech’s digital asset trading infrastructure to expand and optimize its Ethereum holdings. ML Tech, known for its institutional-grade trading strategies and advanced quantitative models, will provide BGLC with tailored investment solutions to maximize returns while ensuring rigorous risk management measures.

“We are pleased to partner with BioNexus Gene Lab Corp to apply our Ethereum strategies to their treasury operations,” said Leo Mindyuk, CEO and CIO of ML Tech. “Our expertise in quantitative trading and non-custodial execution models will help BGLC optimize their Ethereum portfolio while ensuring high transparency and security.”

The partnership is also in line with BGLC’s long-term vision of integrating blockchain technology into its financial operations. BGLC plans to expand its Ethereum reserves through ML Tech’s AI platform, while ensuring liquidity and maintaining control of its assets. The partnership could also open up new and innovative financial structures to the market.

“The implementation of our Ethereum treasury strategy is a testament to our commitment to enhancing shareholder value through digital innovation,” said Sam Tan, CEO of BioNexus Gene Lab Corp. “Partnering with ML Tech allows us to optimize our assets and treasury operations with the support of leading experts in the field.”